BioNTech SE (ETR:22UA)
Germany · Delayed Price · Currency is EUR | Market Cap | 24.02B -9.3% |
| Revenue (ttm) | 3.15B +3.7% |
| Net Income | -571.60M |
| EPS | -2.38 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 63,050 |
| Average Volume | 75,067 |
| Open | 97.50 |
| Previous Close | 98.05 |
| Day's Range | 96.25 - 98.10 |
| 52-Week Range | 73.15 - 119.30 |
| Beta | 1.41 |
| RSI | 59.25 |
| Earnings Date | Mar 10, 2026 |
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]
Financial Performance
Financial StatementsNews
BioNTech (BNTX): New Chief People Officer Joins Management Board
BioNTech (BNTX): New Chief People Officer Joins Management Board
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Boa...
2 Biotech Stocks Set to Rebound in 2026
Following recent challenges, these drugmakers could see solid clinical progress in the next 12 to 18 months. Both could launch products with significant sales potential and ride that wave through the ...
Capital Investment Advisory Services, LLC Sells 2,139 Shares of BioNTech SE (BNTX)
Capital Investment Advisory Services, LLC Sells 2,139 Shares of BioNTech SE (BNTX)
TOTH FINANCIAL ADVISORY CORP Buys 2 Shares of BioNTech SE (BNTX)
TOTH FINANCIAL ADVISORY CORP Buys 2 Shares of BioNTech SE (BNTX)
Unpacking the Latest Options Trading Trends in BioNTech
High-rolling investors have positioned themselves bullish on BioNTech (NASDAQ: BNTX), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's...
Goldman Sachs Upgrades BioNTech (BNTX) to 'Buy' with Increased Price Target | BNTX Stock News
Goldman Sachs Upgrades BioNTech (BNTX) to 'Buy' with Increased Price Target | BNTX Stock News
Biontech SE at JPMorgan Healthcare Conference Transcript
Biontech SE at JPMorgan Healthcare Conference Transcript
BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
2026-01-13. The following slide deck was published by BioNTech SE in conjunction with this event.
BNTX Makes Bullish Cross Above Critical Moving Average
In trading on Tuesday, shares of BioNTech SE (Symbol: BNTX) crossed above their 200 day moving average of $102.63, changing hands as high as $107.52 per share. BioNTech SE shares are currently trading...
BioNTech eyes catalyst-rich 2026 as it advances multi-product oncology strategy
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company's focus areas for 2026, including an overvie...
University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund
PHILADELPHIA--(BUSINESS WIRE)--The University of Pennsylvania (“Penn”), BioNTech SE (“BioNTech”), and OUP (Osage University Partners) announced the launch of the $50 million Penn-BioNTech Innovative T...
BioNTech SE: BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
BioNTech has completed its exchange offer to acquire CureVacAcquisition complements BioNTech's capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturi...
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
MAINZ, Germany, December 18, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, or “the Company”) today announced the closing of its acquisition of CureVac N.V. (Nasdaq: CVAC, “CureVac”) and that the subse...
Noteworthy ETF Inflows: FNDF, APTV, BNTX, NXPI
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab Fundamental International Large Company Index (Symbol: FNDF) wh...
BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart
BioNTech (BNTX) maintains a "Strong Buy" rating, driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. BNTX's gotistobart delivered a 63.1% 12-month OS rate versus 30.3%...
BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options
BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb & Co. (NYSE: BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherap...
BioNTech, Bristol-Myers Squibb Announce Interim Results From Pumitamig Study
(RTTNews) - BioNTech SE (BNTX) and Bristol-Myers Squibb Company (BMY), Tuesday announced the first interim data from a global randomized Phase 2 trial, evaluating pumitamig in patients with locally ad...
BioNTech SE: BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer ("TNBC") show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus c...
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chem...
BioNTech (BNTX) Sees Promising Survival Data in Lung Cancer Trial
BioNTech (BNTX) Sees Promising Survival Data in Lung Cancer Trial
BioNTech SE: BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the firs...